Drug details:
Molecular formula: C₄₃H₅₀N₈O₅S

Standard name: 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid

Synonyms:

4-((11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo(19.4.0.03,8)pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl)benzoic acid 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid Abx MCP zosurabalpin [INN] ZOSURABALPIN [USAN] 4-{(7S,10S,13S)-10-(4-aminobutyl)-7-(3-aminopropyl)-13-[(1H-indol-3-yl)methyl]-12-methyl-8,11,14-trioxo-5,6,7,8,9,10,11,12,13,14,15,16-dodecahydropyrido[2,3-b][1,5,8,11,14]benzothiatetraazacycloheptadecin-17-yl}benzoic acid L-Tryptophanamide, N2-((2-mercapto-3-pyridinyl)methyl)-L-ornithyl-L-lysyl-N-((4'-carboxy-3-mercapto(1,1'-biphenyl)-2-yl)methyl)-N2-methyl-, cyclic (1->3)-thioether L-Tryptophanamide, N2-[(2-mercapto-3-pyridinyl)methyl]-L-ornithyl-L-lysyl-N-[(4'-carboxy-3-mercapto[1,1'-biphenyl]-2-yl)methyl]-N2-methyl-, cyclic (1-->3)-thioether N2.2.2.1,3-anhydro{N2-[(2-{[2-(aminomethyl)-4'-carboxy[1,1'-biphenyl]-3-yl]sulfanyl}pyridin-3-yl)methyl]-L-ornithyl-L-lysyl-N-methyl-L-tryptophan}

Curated SMILES: CN1C(C(=O)NCC2=C(C=CC=C2SC3=C(CNC(C(=O)NC(C1=O)CCCCN)CCCN)C=CC=N3)C4=CC=C(C=C4)C(=O)O)CC5=CNC6=CC=CC=C65

Acinetobacter
Related VF: LPS
Target: LptB2FGC
Drug effect: Targets the LptB2FGC complex within the lipopolysaccharide (LPS) transport system and disrupts outer-membrane assembly.
Max phase: Phase I trial
Publications:
Pahil KS, et al., 2024. A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature 625(7995):572-577.
Que W, et al., 2024. Clinical crusade: zosurabalpin's charge against antibiotic resistance. Trends Mol Med 30(5):420-422.